Tixagevimab/cilgavimab: Difference between revisions
CSV import |
CSV import |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
== Tixagevimab/cilgavimab == | |||
<gallery> | |||
File:Tixagevimab-cilgavimab_binding_SARS-CoV-2_spike_protein_7L7E.png|Tixagevimab-cilgavimab binding SARS-CoV-2 spike protein | |||
</gallery> | |||
Latest revision as of 01:52, 17 February 2025
Tixagevimab/cilgavimab is a combination of two monoclonal antibodies designed for the prevention and treatment of COVID-19. The combination is marketed under the brand name Evusheld by AstraZeneca. It was granted emergency use authorization by the FDA in the United States in December 2021.
Mechanism of Action[edit]
Tixagevimab and cilgavimab are monoclonal antibodies that bind to different, non-overlapping epitopes of the spike protein of SARS-CoV-2, the virus that causes COVID-19. By binding to the spike protein, they prevent the virus from entering human cells, thereby preventing infection.
Clinical Trials[edit]
The effectiveness of tixagevimab/cilgavimab was demonstrated in a Phase 3 clinical trial involving over 5,000 participants. The trial found that the combination reduced the risk of developing symptomatic COVID-19 by 77%.
Side Effects[edit]
Common side effects of tixagevimab/cilgavimab include injection site reactions, headache, and fatigue. Serious side effects are rare but can include allergic reactions.
Authorization[edit]
Tixagevimab/cilgavimab was granted emergency use authorization by the FDA in the United States in December 2021 for the pre-exposure prophylaxis (prevention) of COVID-19 in certain individuals.
